594 followers
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis https://t.co/DtFjfc0jxy
2,167 followers
Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis https://t.co/ZYFpheQra5 #LongCovid #pwLC
12,104 followers
RT @FrontNeurol: New Research: Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-l…
10,646 followers
New Research: Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis: Objective ADAPT+ assessed the long-term safety,… https://t.c